BLAINTRAMUSCULARINJECTABLE
Approved
Jun 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
RYLAZE (asparaginase erwinia chrysanthemi (recombinant)-rywn) by Jazz Pharmaceuticals. Approved for asparagine-specific enzyme [epc]. First approved in 2021.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYLAZE is a recombinant asparaginase Erwinia chrysanthemi enzyme indicated as an asparagine-specific therapeutic agent. It functions as a specialized enzymatic treatment that depletes asparagine, an amino acid critical to certain cancer cell survival. The drug is administered intramuscularly and represents a distinct biologic modality used in hematologic malignancies.
Peak
Peak lifecycle stage indicates a mature, stable commercial infrastructure with established market presence and moderate competitive intensity (30%).
Mechanism of Action
Pharmacologic Class:
Asparagine-specific Enzyme
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RYLAZE offers stability within a peak-lifecycle specialty biologic franchise at Jazz Pharmaceuticals, a mid-sized oncology-focused company. The 0 linked job count suggests either a highly focused team or potential for growth opportunities in niche oncology roles.
Brand ManagerMedical Science Liaison
Worked on RYLAZE at Jazz Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.